Enhanced anti-tumor activity by adenovirus mediated LIF and IL-24 co-expression on glioma cells and its mechanism
Keywords:
gene therapy, bicistronic adenovirus, LIF, IL-24, gliomaAbstract
Objective: Gene therapy on the glioma has been studied for many years, but most studies still remain at the level of single gene therapy. However, the glioma is characterized by a multistep process of genetic and molecular changes to oncogenes and tumor suppressor genes, which limits the efficacy of single gene-mediated therapy due to the difficulty of finding a pivotal gene conferring its occurrence in glioma gene therapy. In this paper, we try to study the anti-tumor effects and mechanism of a recombinant adenoviral vector co-expressing leukemia inhibitory factor (LIF) and interleukin-24 (IL-24) on glioma cells. Materials and Methods: LIF/IL-24 bicistronic adenovirus (Ad-LIF-IL-24) was constructed and preserved by our laboratory. The enhanced growth-suppressing and apoptosis-inducing effect of Ad-LIF-IL-24 on the U251 glioma cells in vitro was assessed, and the expressions of the apoptosis-related genes (bcl-2, bax, and ICE) were determined. Results: Ad-LIF-IL-24 could induce much more cellular apoptosis of U251 glioma cells than either Ad-LIF or Ad-IL-24 alone at the same virus titer. Molecularly, Ad-LIF-IL-24 could significantly enhance the expressions of bax and ICE though it inhibits the expression of bcl-2. Conclusion: Cancer gene therapy combining LIF and IL-24 may constitute a novel and more effective therapeutic strategy for gliomas, with good potential prospects of clinical application.
Downloads
Published
Issue
Section
License
OPEN ACCESS
All the articles of the European Journal of Oncology and Environmental Health are published with open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0 http://creativecommons.org/licenses/by/4.0/). This means that the author(s) retain copyright, but the content is free to download, distribute and adapt for commercial or non-commercial purposes, given appropriate attribution to the original article.
The articles in the previous edition of the Journal (European Journal of Oncology) are made available online with open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0 http://creativecommons.org/licenses/by/4.0/).
Upon submission, author(s) grant the Journal the license to publish their original unpublished work within one year, and the non exclusive right to display, store, copy and reuse the content. The CC-BY Creative Commons attribution license enables anyone to use the publication freely, given appropriate attribution to the author(s) and citing the Journal as the original publisher. The CC-BY Creative Commons attribution license does not apply to third-party materials that display a copyright notice to prohibit copying. Unless the third-party content is also subject to a CC-BY Creative Commons attribution license, or an equally permissive license, the author(s) must comply with any third-party copyright notices.